Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Delayed Graft Function
ProtAffin AG granted Orphan Drug Designation in the US for lead anti-inflammatory product
September 27th, 2008
ProtAffin AG, a biotechnology company developing anti-inflammatory therapeutics that act by targeting cell-surface glycan structures, announced that it has received Orphan Drug Designation in the US from the Food and Drug Administration (FDA) for ProtAffin's lead product PA401 (also designated as Recombinant human CXCL8 mutant). PA401 has been granted Orphan Drug designation in the US for the "prevention of delayed graft function after solid organ transplantation". PA401 is ProtAffin's lead anti-inflammatory product and is a modified form of the human chemokine IL-8 which acts as a potent, targeted anti-inflammatory protein preventing the infiltration of neutrophils which is often seen in...
Source: Law & Health Weekly (2008-09-27)
|
